Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge pursue interdisciplinary translational and experimental medicine programmes in respiratory disease for patient benefit. This centre brings strengths in understanding the genetic and phenotypic diversity of patients with respiratory disease to allow risk stratification and enable the development of patient-specific therapies.
This centre will have greater capabilities following the opening of New Papworth Hospital in 2018, which will collocate UK’s largest cardiothoracic hospital with one of the UK's largest general hospitals providing immunology, infectious diseases and allergy services. The Heart and Lung Research Institute, with a first-into-patient research facility, is also scheduled to open in 2019.
This centre has a focus on mechanistic Phase 0 trials and early Phase I/IIa trials of novel or repurposed compounds, devices, cell-based therapies and gene therapies. Through the centre’s NIHR BRC Cell Phenotyping Hub and links to the NIHR BioResource, genotype-directed deep phenotyping of therapeutic targets can be performed.
The centre offers extensive capabilities, of which some are;
The centre’s commitment to experimental medicine is also supported through participation in the Experimental Medicine Initiative to Explore New Therapies (EMINENT) which includes other TRC centres as well as GSK.
Led by Professor Stefan Marciniak, this centre has expertise in:
Interstitial Lung Disease - Professor Edwin Chilvers, Dr Helen Parfrey and Dr Muhunthan Thillai
Pleural Disease - Professor Stefan Marciniak and Dr Robert Rintoul
Pulmonary Artery Hypertension - Professor Nick Morrell, Dr Mark Toshner, Dr Pepke Zaba
Pulmonary Immune Deficiencies - Prof Floto, Dr Howarth, Dr Sander and Dr Kumararatne
Small airways diseases - Dr Ravi Mahadeva, Dr Gore and Dr Nasser